期刊文献+

球囊损伤大鼠主动脉内皮后血管紧张素Ⅱ2型受体的表达及瑞舒伐他汀的干预作用 被引量:2

Expression of AngiotensinⅡ Type 2 Receptor and the Effects of Rosuvastatin on it After Vascular Balloon Injury in Rats
下载PDF
导出
摘要 目的通过观察血管内皮损伤后血管紧张素Ⅱ2型受体表达的变化及瑞舒伐他汀对其表达的影响,探讨血管紧张素Ⅱ2型受体在再狭窄中的作用。方法建立球囊损伤大鼠主动脉内皮模型,并将大鼠随机分为对照组、手术组和瑞舒伐他汀组,每组分别于术后14天、28天取主动脉组织,并行HE染色观察血管内皮厚度的变化,用逆转录聚合酶链反应检测主动脉组织血管紧张素Ⅱ2型受体mRNA的表达,免疫组织化学法检测主动脉组织血管紧张素Ⅱ2型受体蛋白的表达。结果大鼠主动脉球囊损伤术后14天及28天血管内皮较对照组显著增厚(P<0.01),瑞舒伐他汀治疗14天及28天大鼠主动脉内膜增生较手术组明显减轻。术后14天及28天,手术组血管紧张素Ⅱ2型受体mRNA和蛋白表达较对照组显著升高(P<0.05),瑞舒伐他汀组血管紧张素Ⅱ2型受体mRNA和蛋白表达较手术组增加(P<0.05)。结论瑞舒伐他汀可抑制大鼠主动脉内皮损伤后的血管增生,并上调血管内皮血管紧张素Ⅱ2型受体的表达。 Aim To investigate the expression of angiotentionⅡ type 2 receptor(AT2) and the effect of rosuvastatin on it after vascular balloon injury in rats. Methods Rat models of aortic endothelial denudation were established by 2F balloon catheters.Rats were randomly allocated into three groups: control group,vascular balloon injury group and rosuvastatin treatment group.The expression of AT2 mRNA and protein were investigated at day 14 and 28 after injury by reverse transcription-polymerse chain reaction(RT-PCR) technique and immunohistochemistry method,respectively. Results Significant intimal thickening was observed at 14 days and 28 days after injury.Rosuvastatin significantly prevented intimal thickening at 14 days and 28 days after balloon injury.The expression of AT2 mRNA and protein increased significantly at 14 days and 28 days after injury(P〈0.05),and they increased obviously after rosuvastatin treatment(P〈0.05). Conclusion The expression of AT2 mRNA and protein increased significantly after endothelial injury,and rosuvastatin upregulated the expression of AT2.
出处 《中国动脉硬化杂志》 CAS CSCD 北大核心 2010年第9期709-712,共4页 Chinese Journal of Arteriosclerosis
基金 青岛市科学技术局资助(02-2-kj-yn-25)
关键词 瑞舒伐他汀 球囊损伤 血管紧张素Ⅱ2型受体 Rosuvastatin Balloon Injury AngiotentionⅡType 2 Receptor
  • 相关文献

参考文献3

二级参考文献47

  • 1[1]O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 months[J]. Circulation, 1997;95(5):1126-31
  • 2[2]Osamah H, Mira R, Sorina S, Shlomo K, Michael A. Reduced platelet aggregation after fluvastatin therapy is associated with altered platelet lipid composition and drug binding to the platelets [J]. Br J Clin Pharmacol, 1997;44(1):77- 83
  • 3[3]Ridker PM, Rifai N, Marc A, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The cholesterol and recurrent events (CARE) investigators[ J]. Circulation, 1999; 100(3): 230 - 5
  • 4[4]Guijarro C, Blanco-Colio LM, Ortego M, Alonso C, Ortiz A,Plaza JJ, et al. 3-hydroxy-3-methylglutaryl coenzyme A reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture[J]. Circ Res, 1998;83(5) :490- 500
  • 5[5]Wassmann S, Laufs U, Baumer AT, Muller K, Ahlbory K,Linz W, et al. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species[J]. Hypertension,2001 ;37(6): 1450 - 7
  • 6[6]Wong B, Lumma WC, Smith AM, Sisko JT, Wright SD, Cai TQ. Statins suppress THP-1 cell migration and secretion of matrix metalloproteinase 9 by inhibiting geranylgeranyllation 3 [J].J Leukoc Biol, 2001 ;69(6) :959 - 62
  • 7[7]Su SF, Hsiao CL, Chu CW, Lee BC, Lee TM. Effects of pravastatin on left ventricular mass in patients with hyperlipidemia and essential hypertension [ J ]. Am J Cardiol, 2000; 86(5):514-8
  • 8[8]Patel R, Nagueh SF, Tsybouleva N, Abdellatif M, Lutucuta S,Kopelen HA, et al. Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopthy [J]. Circulation, 2001; 104(3) :317 - 24
  • 9[10]Sadoshima JI, Izumo S. Molecular characterization of angiotensin Ⅱ -induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts[J]. Circ Res, 1993;73(3):413 - 23
  • 10[11]Sadoshima J, Xu Y, Slayter HS, Izumo S. Autocrine release of angiotensin Ⅱ mediates stretch-induced hypertrophy of cardiac myocytes in vitro[J]. Cell, 1993;75(5) :977 - 84

共引文献44

同被引文献20

  • 1张丽丽,戴秋艳.辛伐他汀对血管平滑肌细胞增殖和迁移的影响[J].中国动脉硬化杂志,2008,16(12):943-947. 被引量:10
  • 2Baigent C, Keech A, Keamey PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90056 participants in 14 randomised trials of statins[ J]. Lan- cet, 2005, 366:1 26%278.
  • 3Liao JK. Effects of statins on 3-bydroxy-3-methylglutaryl eoenzyme a reductase inhibition beyond low-density lipoprotein cholesterol [ J ]. Am J Cardiol, 2005, 96 : 24F-33F.
  • 4Lablanche JM, Leone A, Merkely B, et al. Comparison of the effi- cacy of rosuvastatin versus atorvastatin in reducing apolipoprotein B/ apolipoprotein A-1 ratio in patients with acute coronary syndrome: results of the CENTAURUS study[J]. Arch Cardiovasc Dis, 2010, 103(3) : 160-169.
  • 5Nicholls SJ, Brandrup-Wognsen G, Palmer M, et al. Meta-analysis of comparative efficacy of increasing dose of atorvastatin versus rosu- vastatin versus simvastatin on lowering levels of atherogenic lipids (from VOYAGER) [J]. Am J Cardiol, 2010, 105(1) : 69-76.
  • 6Sironi L, Gianazza E, Gelosa P, et al. Rosuvastatin, but not simv- astatin, provides end-organ protection in stroke-prone rats by antiin- flammatory effects[ J ]. Arterioscler Thromb Vasc Biol, 2005,25 : 598-603.
  • 7Chen J, Li D, Schaefer RF, et al. Inhibitory effect of candesartan and rosuvastatin on CD40 and MMPs expression in apo-E knockout mice : novel insights into the role of RAS and dyslipidemia in athero- genesis~ J]. J Cardiovasc Pharmaeol, 2004, 44 : 446-452.
  • 8Veronica DA, Martin D, Lukas E, et al. Rosuvastatin given during reperfusion decreases infarct size and inhibits matrix metalloprotein- ase-2 activity in normocholesterolemic and hypercholesterolemic rab- bits[J]. J Cardiovasc Pharmacol, 2009, 53: 137-144.
  • 9Michael SK, Haralampos JM, Moses SE. An overview of the extra- lipid effects of rosuvastatin [ J ]. J Cardiovasc Pharmacol Therapeu- tics, 2008,13 : 157-174.
  • 10Robert K, Hans MG, Jef JE, et al. Rosuvastatin reduces athero- sclerosis development beyond and independent of its plasma choles- terol-lowering effect in ApoE * 3-leiden transgenie mice evidence for antiinflammatory effects of rosuvastatin[ J]. Circulation, 2003, 108:1 368-374.

引证文献2

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部